Diagnosis and treatment of metastatic and castration resistant prostate cancer became more and more and complex due to the increasing knowledge and understanding of the underlying molecular events and the subsequently deducted innovative medical treatment.
Modern imaging studies in CRPC have become more selective and currently include positron emission tomography, whole body magnetic resonance imaging, immunoscintigraphy besides the traditional studies such as bone scans and computed tomography.
New expert interviews, 29th June, 2015, Amsterdam, The Netherlands
Nakazawa M, Lu C, Chen Y, Paller CJ, Carducci MA, Eisenberger MA, et al.Ann Oncol 2015 Sep;26(9):1859-65.
Efficacy and Safety of Abiraterone Acetate in Elderly (75 Years or Older) Chemotherapy Naïve Patients with Metastatic Castration Resistant Prostate Cancer
Smith MR, Rathkopf DE, Mulders PF, Carles J, Van Poppel H, Li JJ Urol 2015 Nov;194(5):1277-84.
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, et al.Ann Oncol 2015 Aug;26(8):1589-604.
Safety of abiraterone acetate in CASTRATION-resistant prostate cancer patients with concomitant cardiovascular risk factors
Procopio G, Grassi P, Testa I, Verzoni E, Torri V, Salvioni R, et al.Am J Clin Oncol. 2015 Oct;38(5):479-82.
Liu C, Lou W, Zhu Y, Yang JC, Nadiminty N, Gaikwad NW, et al.Cancer Res 2015 Apr 1;75(7):1413-22.
About the editors
- Professor Miller has been Chairman and Professor of Urology for the Department of Urology at the Benjamin Franklin Medical Center, Berlin, Germany, since 1993. In 2007 he became Chairman of the Department of Urology for the entire Charité (Campus Benjamin Franklin, Campus Mitte and Campus Virchow Klinikum). With more than 6000 in-patients per year, the Dep. of Urology at the Charité is one the largest urologicals clinics in Europe.
- Prof Axel S. Merseburger is currently Chairman of the Clinic of Urology at University Hospital Schleswig-Holstein in Lübeck, Germany, having previously served as Vice Chairman of the Department of Urologic Oncology and Director of the Urologic Oncology Programme at Hannover Medical School, Germany. Professor Merseburger obtained his medical degree from Hannover Medical School in 2002 following a 1-year academic research programme in Washington D.C., USA, where he finished his M.D. thesis.